What type of study is this?

FAPα+CAFs: Targeting the Tumor Microenvironment for Revolutionary Cancer Therapies

View Full Paper

Ask AI

Bookmark

Authors

Observational analysis shows enhanced tumor rejection rates in preclinical models, indicating FAPα as a therapeutic target.

FAPα+CAFs correlate with poor prognosis in cancer, and targeting them may improve treatment outcomes.
Agents like 68Ga-FAP-2286 demonstrated 100% tumor rejection in mouse models, highlighting their effectiveness.
Clinical trials are exploring various FAPα-targeted therapies, including imaging agents and immunotherapies.
Enhancements in immune responses through FAP-targeted approaches suggest a promising direction for cancer care.

Ahmad et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark